The clinical use of adjuvants in pneumococcal vaccination: Current status and future perspectives

Human Vaccines

Volumn 7, Issue 2, 2011, Pages 276-280

  Søgaard, Ole Schmeltz ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Elderly; HIV; Immunogenicity; Immunologic adjuvants; Pneumococcal vaccines; Streptococcus pneumoniae; Vaccination

Indexed keywords

ABATACEPT; AGATOLIMOD; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; CORIXA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; INDOMETACIN; PHOSPHORYL LIPID A; PLACEBO; PNEUMOCOCCUS VACCINE; QS 21; QUILIMMUNE; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG FORMULATION; FLU LIKE SYNDROME; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE REACTION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NOTE; PNEUMOCOCCAL INFECTION; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT; VACCINE FAILURE;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS AS TOPIC; HUMANS; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 79952462589     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.2.13919     Document Type: Note

References (46)

1. Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, et al. Pneumococcal vaccination in developing countries. Lancet 2006; 367:1880-2. (Pubitemid 43842066)
2. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902.
3. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1-24.
4. Obaro SK, Madhi SA. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining or redefining? Lancet Infect Dis 2006; 6:150-61. (Pubitemid 43267641)
5. Lynch JP, III, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors and strategies for prevention. Semin Respir Crit Care Med 2009; 30:189-209.
6. Rudan I, Campbell H. The deadly toll of S pneumoniae and H. influenzae type b. Lancet 2009; 374:854-6.
7. Pneumococcal conjugate vaccine for childhood immunization. WHO position paper. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record/Health Section of the Secretariat of the League of Nations 2007; 82:93-104.
8. Trotter C, Scott P, Huss A, Egger M. Pneumococcal polysaccharide vaccine effectiveness: study quality must not be ignored. Lancet Infect Dis 2008; 8:664.
9. Jefferson T. Pneumococcal vaccines: confronting the confounders. Lancet 2009; 373:2008-9.
10. Simberkoff MS, El Sadr W, Schiffman G, Rahal JJ Jr. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Am Rev Respir Dis 1984; 130:1174-6.
11. Vila-Corcoles A. Advances in pneumococcal vaccines: what are the advantages for the elderly? Drugs Aging 2007; 24:791-800.
12. Ortqvist A, Henckaerts I, Hedlund J, Poolman J. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly. Vaccine 2007; 25:2445-50. (Pubitemid 46389428)
13. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11. (Pubitemid 30364659)
14. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58.
15. Pedersen R, Lohse N, Ostergaard L, Søgaard O. The effectiveness of pneumococcal polysaccharide vaccination among HIV-infected adults: a systematic review. HIV Med 2010; Nov 8. doi. 10.1111/j.1468-1293.2010.00892.x.
16. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95. (Pubitemid 30167436)
17. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22.
18. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297:1784-92. (Pubitemid 46658647)
19. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunology and cell biology 2004; 82:488-96. (Pubitemid 39421058)
20. Schmidt CS, Morrow WJ, Sheikh NA. Smart adjuvants. Expert Rev Vaccines 2007; 6:391-400.
21. Flebbe LM, Braley-Mullen H. Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens. Cell Immunol 1986; 99:119-27.
22. Graber CD, Goust JM, Glassman AD, Kendall R, Loadholt CB. Immunomodulating properties of dimethylglycine in humans. J Infect Dis 1981; 143:101-5. (Pubitemid 11152605)
23. Lafferty WP, Selinger DS, Schiffman G, Goodwin JS. Response to pneumococcal vaccine in the elderly: no enhancement by indomethacin. J Immunopharmacol 1981; 3:241-50. (Pubitemid 12141608)
24. Tovey MG, Lallemand C. Adjuvant activity of cytokines. Methods Mol Biol 2010; 626:287-309.
25. Buchanan RM, Briles DE, Arulanandam BP, Westerink MA, Raeder RH, Metzger DW. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 2001; 19:2020-8. (Pubitemid 32178351)
26. Hedlund J, Langer B, Konradsen HB, Ortqvist A. Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine 2001; 20:164-9. (Pubitemid 32905329)
27. DeVelasco EA, Dekker HA, Antal P, Jalink KP, van Strijp JA, Verheul AF, et al. Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines. Vaccine 1994; 12:1419-22. (Pubitemid 24347929)
28. Garg M, Subbarao B. Immune responses of systemic and mucosal lymphoid organs to Pnu-Imune vaccine as a function of age and the efficacy of monophosphoryl lipid A as an adjuvant. Infect Immun 1992; 60:2329-36.
29. CareCureCommunity. Antigenics' Quilimmune-P Pneumococcal Vaccine Induces Potent Immune Response in the Elderly. 2001. http://sci.rutgers.edu/forum/ showthread.php?t = 4298. Accessed 5.10.2010.
30. The Free Library. Aquila Announces Initial Results Of Phase II Clinical Trial Of Quilimmune-P(TM) To Prevent Pneumococcal Infections 1998. http://www.thefreel ibrary.com/-/print /PrintArticle.aspx?id = 53080854. Accessed 5.10.2010.
31. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003; 2:219-29. (Pubitemid 36559927)
32. Vernacchio L, Bernstein H, Pelton S, Allen C, MacDonald K, Dunn J, et al. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 2002; 20:3658-67. (Pubitemid 35223395)
33. Safdar A, Rodriguez GH, Rueda AM, Wierda WG, Ferrajoli A, Musher DM, et al. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer 2008; 113:383-7.
34. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007; 9:38.
35. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nature Rev Drug Discov 2006; 5:471-84. (Pubitemid 44136959)
36. Sogaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010; 51:42-50.
37. Yin JZ, Bell MK, Thorbecke GJ. Effect of various adjuvants on the antibody response of mice to pneumococcal polysaccharides. J Biol Response Mod 1989; 8:190-205. (Pubitemid 19086818)
38. Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 2010; 9:308-24.
39. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13:655-92.
40. Daubenberger CA. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther 2007; 9:45-52. (Pubitemid 46438448)
41. Taillardet M, Haffar G, Mondiere P, Asensio MJ, Gheit H, Burdin N, et al. The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells. Blood 2009; 114:4432-40.
42. Taillardet M, Haffar G, Mondiere P, Asensio MJ, Pleau-Pison T, Burdin N, et al. Toll-like receptor agonists allow generation of long-lasting antipneumococcal humoral immunity in response to a plain polysaccharidic vaccine. J Infect Dis 2010; 202:470-9.
43. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199-202. (Pubitemid 35471246)
44. Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 2001; 20:148-57. (Pubitemid 32905327)
45. Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med 2010; 88:135-42.
46. Basset A, Thompson CM, Hollingshead SK, Briles DE, Ades EW, Lipsitch M, et al. Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun 2007; 75:5460-4.